Globionic

Globionic is a biotechnology company focused on the discovery and development of novel therapeutics targeting G protein-coupled receptors (GPCRs). The company leverages a proprietary platform to identify and optimize small molecules and peptides that can modulate GPCR activity with high specificity. Their primary research focus is on metabolic disorders, including obesity and type 2 diabetes, as well as inflammatory conditions. By utilizing advanced structural biology and computational screening, Globionic aims to address unmet medical needs in chronic disease management. The company is currently in the pre-clinical stage, advancing several internal programs toward candidate selection.